1. Cancer Cure and Consequences on Survivorship Care: Position Paper from the Italian Alliance Against Cancer (ACC) Survivorship Care Working Group.
- Author
-
Maso, Luigino Dal, Santoro, Armando, Iannelli, Elisabetta, De Paoli, Paolo, Minoia, Carla, Pinto, Monica, Bertuzzi, Alexia Francesca, Serraino, Diego, De Angelis, Roberta, Trama, Annalisa, Haupt, Riccardo, Pravettoni, Gabriella, Perrone, Maria, De Lorenzo, Francesco, and Tralongo, Paolo
- Subjects
CANCER patient care ,RIGHT to be forgotten ,CANCER relapse ,TESTICULAR cancer ,PROSTATE cancer patients ,INDIVIDUALIZED medicine ,MEDICAL care - Abstract
Aimac), Rome, Italy;
6 Alleanza Contro il Cancro, Rome, Italy;7 SC Haematology, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy;8 Rehabilitation Medicine Unit, Strategic Health Services Department, Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy;9 Department of Oncology and Molecular Medicine, Italian National Institute of Health (ISS), Rome, Italy;10 Evaluative Epidemiology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy;11 DOPO Clinic, Department of Pediatric Haematology/Oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy;12 Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy;13 Applied Research Division for Cognitive and Psychological Science, IEO European Institute of Oncology IRCCS, Milan, Italy;14 Psychology Unit, IRCCS Regina Elena Cancer Institute, Rome, Italy;15 Medical Oncology Unit, Umberto I Hospital, Department of Oncology, RAO, Siracusa, ItalyCorrespondence: Luigino Dal Maso, Epidemiologia Oncologica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Via Franco Gallini 2, Aviano (PN), 33081, Italy, Tel +39 0434 659354, Email [email protected] Paolo Tralongo, Medical Oncology Unit, Umberto I Hospital, Department of Oncology, RAO, Via Giuseppe Testaferrata 1, Siracusa, 96100, Italy, Tel +39 0931 724 464, Email [email protected] A multidisciplinary panel of experts and cancer patients developed a position paper to highlight recent evidence on "cancer cure" (ie, the possibility of achieving the same life expectancy as the general population) and discuss the consequences of this concept on follow-up and rehabilitation strategies. The aim is to inform clinicians, patients, and health-care policy makers about strategies of survivorship care for cured cancer patients and consequences impacting patient lives, spurring public health authorities and research organizations to implement resources to the purpose. Two identifiable, measurable, and reproducible indicators of cancer cure are presented. Cure fraction (CF) is > 60% for breast and prostate cancer patients, > 50% for colorectal cancer patients, and > 70% for patients with melanoma, Hodgkin lymphoma, and cancers of corpus uteri, testis (> 90%), and thyroid. CF was > 65% for patients diagnosed at ages 15– 44 years and 30% for those aged 65– 74 years. Time-to-cure was consistently < 1 year for thyroid and testicular cancer patients and < 10 years for patients with colorectal and cervical cancers, melanoma, and Hodgkin lymphoma. The working group agrees that the evidence allows risk stratification of cancer patients and implementation of personalized care models for timely diagnosis, as well as treatment of possible cancer relapses or related long-term complications, and preventive measures aimed at maintaining health status of cured patients. These aspects should be integrated to produce an appropriate follow-up program and survivorship care plan(s), avoiding stigma and supporting return to work, to a reproductive life, and full rehabilitation. The "right to be forgotten" law, adopted to date only in a few European countries, may contribute to these efforts for cured patients. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF